Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Drug

RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial

Fineline Cube Oct 28, 2024

RiboX Therapeutics, a Shanghai-based developer of circular RNA (circRNA) therapies, has announced that it has...

Company Drug

AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment

Fineline Cube Oct 28, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia

Fineline Cube Oct 28, 2024

MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of...

Policy / Regulatory

NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status

Fineline Cube Oct 28, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) released a...

Company Medical Device

Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening

Fineline Cube Oct 28, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, announced last...

Company Drug

Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China

Fineline Cube Oct 28, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...

Company Deals

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania

Fineline Cube Oct 28, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...

Company Deals

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development

Fineline Cube Oct 28, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...

Company Deals Drug

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS

Fineline Cube Oct 28, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...

Company Drug

Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications

Fineline Cube Oct 28, 2024

Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...

Company Drug

BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option

Fineline Cube Oct 28, 2024

BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...

Company Drug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

Fineline Cube Oct 28, 2024

RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...

Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports

Fineline Cube Oct 28, 2024

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China

Fineline Cube Oct 27, 2024

RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...

Company Medical Device

Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment

Fineline Cube Oct 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...

Company Drug

Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center

Fineline Cube Oct 26, 2024

On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...

Company

TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs

Fineline Cube Oct 26, 2024

TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...

Policy / Regulatory

Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024

Fineline Cube Oct 25, 2024

The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...

Company Drug

BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy

Fineline Cube Oct 25, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...

Company

Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion

Fineline Cube Oct 25, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...

Posts pagination

1 … 323 324 325 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.